{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fulvestrant&page=3", "query": { "intervention": "fulvestrant", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 294, "total_pages": 30, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fulvestrant&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=fulvestrant&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T00:48:46.290Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations" ], "interventions": [ { "name": "Neratinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 582, "start_date": "2013-09-30", "completion_date": "2023-01-02", "has_results": true, "last_update_posted_date": "2024-03-12", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 26 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01953926" }, { "nct_id": "NCT04031885", "title": "A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Standard Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 4, "start_date": "2019-08-14", "completion_date": "2020-08-11", "has_results": true, "last_update_posted_date": "2021-08-24", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 55, "location_summary": "Avondale, Arizona • Phoenix, Arizona • Yuma, Arizona + 51 more", "locations": [ { "city": "Avondale", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04031885" }, { "nct_id": "NCT01296555", "title": "A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Cancers", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "GDC-0032", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 674, "start_date": "2011-03-16", "completion_date": "2021-06-25", "has_results": true, "last_update_posted_date": "2024-07-31", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 27, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01296555" }, { "nct_id": "NCT05251714", "title": "CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "Breast Cancer" ], "interventions": [ { "name": "CFI-402257", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Treadwell Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2022-05-27", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2025-05-18", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 4, "location_summary": "Columbus, Ohio • San Antonio, Texas • West Valley City, Utah + 1 more", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" }, { "city": "West Valley City", "state": "Utah" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05251714" }, { "nct_id": "NCT05262400", "title": "A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "PF-07220060 + PF-07104091 combination dose escalation", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + fulvestrant dose expansion", "type": "DRUG" }, { "name": "PF-07104091 + PF-07220060 + letrozole dose expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 235, "start_date": "2022-03-14", "completion_date": "2027-02-26", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 12, "location_summary": "Los Angeles, California • Santa Monica, California • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05262400" }, { "nct_id": "NCT04851613", "title": "Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Afuresertib", "type": "DRUG" }, { "name": "Afuresertib/placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Laekna Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2022-02-18", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 6, "location_summary": "Santa Monica, California • Atlanta, Georgia • Iowa City, Iowa + 3 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Jackson", "state": "Mississippi" }, { "city": "Burlington", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT04851613" }, { "nct_id": "NCT04214288", "title": "A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced ER-Positive HER2-Negative Breast Cancer" ], "interventions": [ { "name": "AZD9833", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 240, "start_date": "2020-04-22", "completion_date": "2027-06-16", "has_results": true, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Long Beach, California • Fort Myers, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214288" }, { "nct_id": "NCT05054374", "title": "A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Cancer Stage IV", "HER2-negative Breast Cancer", "Solid Carcinoma", "MEK1 Gene Mutation", "MEK2 Gene Mutation", "Metastatic Breast Cancer" ], "interventions": [ { "name": "Mirdametinib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2021-09-14", "completion_date": "2023-10-26", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 4, "location_summary": "Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more", "locations": [ { "city": "Middletown", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05054374" }, { "nct_id": "NCT06409390", "title": "Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Taxotere", "type": "DRUG" }, { "name": "Cytoxan", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Sacituzumab govitecan", "type": "DRUG" }, { "name": "Xeloda", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Ribociclib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2024-08-14", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06409390" }, { "nct_id": "NCT00534417", "title": "Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Accelerated Community Oncology Research Network", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 41, "start_date": "2007-10", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2013-02-01", "last_synced_at": "2026-10-24T00:48:46.290Z", "location_count": 10, "location_summary": "Miami, Florida • Athens, Georgia • Augusta, Georgia + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00534417" } ] }